CTI BioPharma Corp. Sustainability Profile
CTI BioPharma Corp., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 1991, the company has made substantial strides in developing innovative therapies for blood-related cancers, particularly focusing on conditions such as leukaemia and lymphoma. CTI BioPharma is renowned for its flagship product, pacritinib, a unique treatment designed for patients with myelofibrosis, a rare bone marrow disorder. This product stands out due to its targeted mechanism of action, offering hope to those with limited treatment options. Over the years, CTI BioPharma has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a commitment to advancing patient care, CTI BioPharma continues to drive innovation in oncology therapeutics.
DitchCarbon Score
How does CTI BioPharma Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CTI BioPharma Corp.'s score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CTI BioPharma Corp., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Swedish Orphan Biovitrum AB (publ), which may influence its climate commitments and reporting practices. While CTI BioPharma Corp. has not established its own reduction targets or climate pledges, it is important to note that it inherits initiatives and performance metrics from its parent company, Swedish Orphan Biovitrum AB (publ). This includes potential commitments to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are cascaded down from the parent organisation. As of now, CTI BioPharma Corp. has not publicly outlined specific reduction initiatives or targets. The company’s climate strategy may align with broader industry trends focusing on sustainability and emissions reduction, but specific details remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 150,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,450,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is CTI BioPharma Corp.'s Industry?
How Carbon Intensive is CTI BioPharma Corp.'s Location?
CTI BioPharma Corp.'s Scope 3 Categories Breakdown
CTI BioPharma Corp.'s Scope 3 emissions, which increased by 30% last year and increased significantly since 2017, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
CTI BioPharma Corp.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CTI BioPharma Corp. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
